ALK and lung adenocarcinoma: Mutations of the epidermal growth factor receptor (EGFR) gene and chromosomal rearrangement of the anaplastic lymphoma kinase (ALK) gene were among the first established molecular targets for therapy in lung adenocarcinoma.